Evidence map›Paper›PMID 21041727›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2010

Differential TRAF3 utilization by a variant human CD40 receptor with enhanced signaling.

Anna L Peters, Gail A Bishop

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Anna L PetersMedical Scientist Training Program and Immunology Graduate Program, University of Iowa, Iowa City, IA 52240, USA.
Gail A Bishop
Iowa City VA Medical Center · USUniversity of Iowa · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007337 · NIGMS · UNIVERSITY OF IOWA · PI GEYER, PAMELA K., LENTZ, STEVEN R · 1985 to 2020
$15.9M
Mechanisms of Alteration of B Lymphocyte Function by LMP1R01CA099997 · NCI · UNIVERSITY OF IOWA · PI BISHOP, GAIL A. · 2003 to 2013
$3.2M
The Roles of TRAF3 in Lymphocyte SignalingR01AI028847 · NIAID · UNIVERSITY OF IOWA · PI BISHOP, GAIL A. · 1996 to 2011
$3.1M
TRAFs and Rafts in CD40 Signaling to B LymphocytesR01AI049993 · NIAID · UNIVERSITY OF IOWA · PI BISHOP, GAIL A. · 2001 to 2009
$2.7M
Regulation of lymphocyte receptor signaling by TRAF interactionsR56AI049993 · NIAID · UNIVERSITY OF IOWA · PI BISHOP, GAIL A. · 2010 to 2010
$374k
Understanding TRAF3-mediated regulation of T lymphocyte functionsR56AI028847 · NIAID · UNIVERSITY OF IOWA · PI BISHOP, GAIL A. · 2013 to 2013
$227k
REGULATION OF CLASS II--MEDIATED B CELL DIFFERENTIATIONR29AI028847 · NIAID · UNIVERSITY OF IOWA · PI BISHOP, GAIL A. · 1990 to 1994
–
NCI NIH HHS CA099997NCI NIH HHS R01 CA099997NIAID NIH HHS AI28847NIAID NIH HHS AI49993NIAID NIH HHS R01 AI028847NIAID NIH HHS R01 AI049993NIAID NIH HHS R56 AI028847NIAID NIH HHS R56 AI049993NIGMS NIH HHS T32 GM007337
6 · The paper itself

Abstract

CD40 is required for T cell-dependent humoral immunity, but it can also contribute to the pathogenesis of autoimmunity and B cell malignancy. The TNFR-associated factor (TRAF)2 and TRAF6 adaptor proteins are positive regulators of CD40 signaling required to activate downstream kinase cascades and transcription factors. In contrast, TRAF3 can serve as a negative regulator of CD40 signaling, and CD40 signals are amplified in TRAF3(-/-) B cells. We previously reported a gain-of-function polymorphism of the human CD40 receptor, hCD40-P227A, which signals in an amplified manner to B lymphocytes. In this study, we show that hCD40-P227A binds more TRAF3 and TRAF5, as well as certain associated proteins, than wild-type-CD40. Studies in TRAF-deficient B cell lines revealed that hCD40-P227A uses TRAF3 as a positive rather than negative regulator. Although located outside of any known TRAF binding sites, the P227A polymorphism can alter TRAF binding and dramatically changes the role played by TRAF3 in CD40 signaling.

Indexed as

Amino Acid SequenceAmino Acid SubstitutionAnimalsBinding SitesCD40 AntigensCell LineClone CellsGenetic VariationHumansInterleukin-6MiceMolecular Sequence DataPolymorphism, GeneticSignal TransductionTNF Receptor-Associated Factor 3TNF Receptor-Associated Factor 6CD40 AntigensIL6 protein, humanInterleukin-6TNF Receptor-Associated Factor 3TNF Receptor-Associated Factor 6TRAF3 protein, human

Identifiers

PMID21041727
PMCPMC3040440
OpenAlexW2166495096

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.